Discovery of a biarylamide series of potent, state-dependent NaV1.7 inhibitors.

[1]  Michael A Rossi,et al.  Benzoxazolinone aryl sulfonamides as potent, selective Nav1.7 inhibitors with in vivo efficacy in a preclinical pain model. , 2017, Bioorganic & medicinal chemistry letters.

[2]  Edward C Sherer,et al.  Discovery of selective, orally bioavailable, N-linked arylsulfonamide Nav1.7 inhibitors with pain efficacy in mice. , 2017, Bioorganic & medicinal chemistry letters.

[3]  Roman Shimanovich,et al.  Sulfonamides as Selective NaV1.7 Inhibitors: Optimizing Potency, Pharmacokinetics, and Metabolic Properties to Obtain Atropisomeric Quinolinone (AM-0466) that Affords Robust in Vivo Activity. , 2017, Journal of medicinal chemistry.

[4]  R. Fremeau,et al.  Sulfonamides as Selective NaV1.7 Inhibitors: Optimizing Potency and Pharmacokinetics While Mitigating Metabolic Liabilities. , 2017, Journal of Medicinal Chemistry.

[5]  A. Guzman-Perez,et al.  Discovery and hit-to-lead evaluation of piperazine amides as selective, state-dependent NaV1.7 inhibitors. , 2017, MedChemComm.

[6]  R. Fremeau,et al.  Sulfonamides as Selective NaV1.7 Inhibitors: Optimizing Potency and Pharmacokinetics to Enable in Vivo Target Engagement. , 2016, ACS medicinal chemistry letters.

[7]  Dong Liu,et al.  Application of a Parallel Synthetic Strategy in the Discovery of Biaryl Acyl Sulfonamides as Efficient and Selective NaV1.7 Inhibitors. , 2016, Journal of medicinal chemistry.

[8]  Alex Phipps,et al.  Clinical Micro-Dose Studies to Explore the Human Pharmacokinetics of Four Selective Inhibitors of Human Nav1.7 Voltage-Dependent Sodium Channels , 2016, Clinical Pharmacokinetics.

[9]  Shifeng Liu,et al.  Discovery of Aryl Sulfonamides as Isoform-Selective Inhibitors of NaV1.7 with Efficacy in Rodent Pain Models. , 2016, ACS medicinal chemistry letters.

[10]  Jun Li,et al.  Structural basis of Nav1.7 inhibition by an isoform-selective small-molecule antagonist , 2015, Science.

[11]  Manuel de Lera Ruiz,et al.  Voltage-Gated Sodium Channels: Structure, Function, Pharmacology, and Clinical Indications. , 2015, Journal of medicinal chemistry.

[12]  M. D. de Groot,et al.  Voltage sensor interaction site for selective small molecule inhibitors of voltage-gated sodium channels , 2013, Proceedings of the National Academy of Sciences.

[13]  R. Penland,et al.  Cardiac Safety Implications of hNav1.5 Blockade and a Framework for Pre-Clinical Evaluation , 2012, Front. Pharmacol..

[14]  S. Cook,et al.  A Point Mutation at F1737 of the Human Nav1.7 Sodium Channel Decreases Inhibition by Local Anesthetics , 2011, Journal of neurogenetics.

[15]  S. Arneric,et al.  A novel slow-inactivation-specific ion channel modulator attenuates neuropathic pain , 2011, PAIN®.

[16]  M. Gleeson Generation of a set of simple, interpretable ADMET rules of thumb. , 2008, Journal of medicinal chemistry.

[17]  M. Dubé,et al.  Loss‐of‐function mutations in the Nav1.7 gene underlie congenital indifference to pain in multiple human populations , 2007, Clinical genetics.

[18]  Hussain Jafri,et al.  An SCN9A channelopathy causes congenital inability to experience pain , 2006, Nature.

[19]  John N. Wood,et al.  SCN9A Mutations in Paroxysmal Extreme Pain Disorder: Allelic Variants Underlie Distinct Channel Defects and Phenotypes , 2006, Neuron.

[20]  B. Ding,et al.  Mutations in SCN9A, encoding a sodium channel alpha subunit, in patients with primary erythermalgia , 2004, Journal of Medical Genetics.

[21]  W. Catterall,et al.  Differential interactions of lamotrigine and related drugs with transmembrane segment IVS6 of voltage-gated sodium channels , 2003, Neuropharmacology.